Complete Filing Data
Kairos Pharma, LTD. reported Stockholders Equity of $6.34 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Kairos Pharma, LTD. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income Loss | -$5.4M | -$2.6M | -$1.8M |
| Research And Development Expense | $2.1M | $414.0K | $82.0K |
| Operating Income Loss | -$5.6M | -$2.3M | -$1.7M |
| Operating Expenses | $5.6M | $2.3M | $1.7M |
| Nonoperating Income Expense | $125.0K | -$260.0K | -$98.0K |
| General And Administrative Expense | $3.4M | $1.9M | $1.6M |
| Interest Expense Nonoperating | $35.0K | $42.0K | |
| Amortization Of Intangible Assets | $160.0K | $160.0K | $160.0K |
| Other Nonoperating Expense | $670.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|
| Net Income Loss | -$1.4M | -$1.4M | -$1.3M | -$1.0M | -$253.0K | -$323.0K | -$312.0K |
| Research And Development Expense | $608.0K | $496.0K | $493.0K | $14.0K | $63.0K | $165.0K | $33.0K |
| Operating Income Loss | -$1.4M | -$1.5M | -$1.3M | -$383.0K | -$222.0K | -$287.0K | -$287.0K |
| Operating Expenses | $1.4M | $1.5M | $1.3M | $383.0K | $222.0K | $287.0K | $287.0K |
| Nonoperating Income Expense | $37.0K | $34.0K | $4.0K | -$664.0K | -$31.0K | -$36.0K | -$25.0K |
| General And Administrative Expense | $827.0K | $960.0K | $773.0K | $369.0K | $159.0K | $122.0K | $254.0K |
| Interest Expense Nonoperating | $12.0K | $12.0K | $16.0K | $15.0K | |||
| Amortization Of Intangible Assets | $40.0K | $40.0K | |||||
| Other Nonoperating Expense | $537.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $6.3M | $4.8M | -$2.1M | -$1.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.5M | $1.3M | $93.0K | $437.0K |
| Amortization Of Debt Discount Premium | $154.0K | $56.0K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $3.2M | $1.2M | -$344.0K | |
| Retained Earnings Accumulated Deficit | -$14.3M | -$8.8M | -$6.2M | |
| Liabilities Current | $199.0K | $992.0K | $2.4M | |
| Liabilities And Stockholders Equity | $6.5M | $5.8M | $965.0K | |
| Intangible Assets Net Excluding Goodwill | $62.0K | $222.0K | $382.0K | |
| Common Stock Value | $21.0K | $14.0K | $11.0K | |
| Assets Noncurrent | $1.2M | $1.6M | $864.0K | |
| Assets Current | $5.4M | $4.2M | $101.0K | |
| Assets | $6.5M | $5.8M | $965.0K | |
| Accounts Payable And Accrued Liabilities Current | $199.0K | $992.0K | $2.4M | |
| Prepaid Expense And Other Assets Current | $51.0K | $38.0K | $8.0K | |
| Deferred Costs | $1.1M | $1.4M | $482.0K | |
| Liabilities | $992.0K | $3.0M | ||
| Cash | $4.5M | $1.3M | ||
| Reclassification Of Deferred Offering Costs To Shareholders Equity | $614.0K | $872.0K | ||
| Conversion Of Convertible Notes Payable And Accrued Interest To Shareholders Equity | $884.0K | |||
| Cash And Cash Equivalents At Carrying Value | $4.5M | $1.3M | ||
| Repayments Of Notes Payable | $142.0K | |||
| Issuance Of Common Shares For Deferred Offering Costs | 327.0K | 1.4M | ||
| Debt Instrument Unamortized Discount | $105.0K | |||
| Convertible Long Term Notes Payable | $638.0K | |||
| Conversion Of Amounts Due To Related Parties To Shareholders Equity | $4.0K | |||
| Conversion Of Accounts Payable To Shareholders Equity | $1.3M | |||
| Issuance Of Convertible Notes Payable Recorded As Debt Discount | $49.0K | $68.0K | ||
| Fair Value Of Warrants Issued In Connection With Convertible Notes Payable | $29.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $7.7M | $6.0M | $7.1M | $3.3M | -$2.7M | -$2.4M | -$1.9M | -$1.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.6M | $3.0M | $3.6M | $3.2M | $21.0K | $40.0K | $99.0K | |
| Amortization Of Debt Discount Premium | $115.0K | $19.0K | $20.0K | $10.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $2.3M | -$53.0K | ||||||
| Retained Earnings Accumulated Deficit | -$12.9M | -$11.5M | -$10.1M | -$7.8M | ||||
| Liabilities Current | $402.0K | $676.0K | $805.0K | $1.7M | ||||
| Liabilities And Stockholders Equity | $8.1M | $6.7M | $7.9M | $5.0M | ||||
| Intangible Assets Net Excluding Goodwill | $102.0K | $142.0K | $182.0K | $262.0K | ||||
| Common Stock Value | $21.0K | $18.0K | $16.0K | $13.0K | ||||
| Assets Noncurrent | $1.4M | $1.8M | $1.9M | $262.0K | ||||
| Assets Current | $6.7M | $4.8M | $6.1M | $4.7M | ||||
| Assets | $8.1M | $6.7M | $7.9M | $5.0M | ||||
| Accounts Payable And Accrued Liabilities Current | $402.0K | $676.0K | $805.0K | $1.5M | ||||
| Prepaid Expense And Other Assets Current | $24.0K | $88.0K | $55.0K | $10.0K | ||||
| Deferred Costs | $1.3M | $1.7M | $1.7M | |||||
| Liabilities | $1.7M | |||||||
| Cash | $5.6M | $3.0M | $3.6M | |||||
| Reclassification Of Deferred Offering Costs To Shareholders Equity | ||||||||
| Conversion Of Convertible Notes Payable And Accrued Interest To Shareholders Equity | ||||||||
| Cash And Cash Equivalents At Carrying Value | $5.6M | $3.0M | $3.6M | |||||
| Repayments Of Notes Payable | ||||||||
| Issuance Of Common Shares For Deferred Offering Costs | 328.0K | |||||||
| Debt Instrument Unamortized Discount | ||||||||
| Convertible Long Term Notes Payable | ||||||||
| Conversion Of Amounts Due To Related Parties To Shareholders Equity | ||||||||
| Conversion Of Accounts Payable To Shareholders Equity | ||||||||
| Issuance Of Convertible Notes Payable Recorded As Debt Discount | ||||||||
| Fair Value Of Warrants Issued In Connection With Convertible Notes Payable |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$3.4M | -$4.0M | $81.0K |
| Net Cash Provided By Used In Financing Activities | $6.7M | $5.1M | -$425.0K |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | -$793.0K | $404.0K | $772.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $13.0K | $30.0K | $8.0K |
| Payments Of Financing Costs | $390.0K | $425.0K | |
| Proceeds From Notes Payable | $142.0K | ||
| Increase Decrease In Vendor Advances | $2.4M | ||
| Proceeds From Issuance Initial Public Offering | $5.5M | ||
| Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition | |||
| Proceeds From Issuance Of Warrants | $3.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q3 2024 | Q1 2024 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$714.0K | $36.0K | |
| Net Cash Provided By Used In Financing Activities | $3.1M | -$89.0K | |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | -$187.0K | $310.0K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $17.0K | $11.0K | |
| Payments Of Financing Costs | $89.0K | ||
| Proceeds From Notes Payable | |||
| Increase Decrease In Vendor Advances | $636.0K | ||
| Proceeds From Issuance Initial Public Offering | |||
| Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition | $5.0K | ||
| Proceeds From Issuance Of Warrants | $3.1M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 18.4M | 11.4M | 10.4M |
| Weighted Average Number Of Diluted Shares Outstanding | 18.4M | 11.4M | 10.4M |
| Earnings Per Share Diluted | $-0.30 | $-0.23 | $-0.17 |
| Earnings Per Share Basic | $-0.30 | $-0.23 | $-0.17 |
| Preferred Stock Shares Authorized | 20.0M | 20.0M | 20.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 |
| Common Stock Shares Outstanding | 20.8M | 13.7M | 10.6M |
| Common Stock Shares Issued | 20.8M | 13.7M | 10.6M |
| Fair Value Of Common Shares Issued In Connection With Conversion Of Accounts Payable | 670.0K | ||
| Stock Issued During Period Value Common Shares Issued For Cash Through Equity Line Of Credit | 3.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 20.2M | 17.2M | 15.9M | 10.9M | 10.6M | 10.6M | 10.3M |
| Weighted Average Number Of Diluted Shares Outstanding | 20.2M | 17.2M | 15.9M | 10.9M | 10.6M | 10.6M | 10.3M |
| Earnings Per Share Diluted | $-0.07 | $-0.08 | $-0.08 | $-0.10 | $-0.02 | $-0.03 | $-0.03 |
| Earnings Per Share Basic | $-0.07 | $-0.08 | $-0.08 | $-0.10 | $-0.02 | $-0.03 | $-0.03 |
| Preferred Stock Shares Authorized | 20.0M | 20.0M | 20.0M | 20.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Common Stock Shares Outstanding | 20.8M | 17.7M | 15.8M | 12.8M | |||
| Common Stock Shares Issued | 20.8M | 17.7M | 15.8M | 12.8M | |||
| Fair Value Of Common Shares Issued In Connection With Conversion Of Accounts Payable | |||||||
| Stock Issued During Period Value Common Shares Issued For Cash Through Equity Line Of Credit | 3.0M | 210.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Additional Paid In Capital | $20.6M | $13.6M | $4.1M |
| Stock Issued During Period Value New Issues | $4.7M | ||
| Stock Issued During Period Value Conversion Of Convertible Securities | $884.0K | ||
| Adjustments To Additional Paid In Capital Warrant Issued | $29.0K | ||
| Stock Issued During Period Value Restricted Stock Award Gross | $482.0K | $218.0K | |
| Stock Issued During Period Value Issued For Services | $7.0K | ||
| Stock Issued During Period Value Conversion Of Units | $1.8M | ||
| Vendor Advances Net | $845.0K | $2.9M | |
| Fair Value Of Vested Restricted Stock Units | $482.0K | $218.0K | |
| Issuance Of Common Shares For Vendor Advances | 157.0K | 500.0K | |
| Investment Income Net | $125.0K | ||
| Fair Value Of Restricted Stock Units | $218.0K | ||
| Vendor Advances Current |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q1 2024 |
|---|---|---|---|---|---|
| Additional Paid In Capital | $20.5M | $17.5M | $16.7M | $11.2M | |
| Stock Issued During Period Value New Issues | $4.7M | ||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $884.0K | ||||
| Adjustments To Additional Paid In Capital Warrant Issued | $29.0K | ||||
| Stock Issued During Period Value Restricted Stock Award Gross | $70.0K | $77.0K | $76.0K | $5.0K | |
| Stock Issued During Period Value Issued For Services | $7.0K | ||||
| Stock Issued During Period Value Conversion Of Units | $1.5M | ||||
| Vendor Advances Net | $1.1M | $1.7M | $2.4M | ||
| Fair Value Of Vested Restricted Stock Units | $76.0K | $20.0K | |||
| Issuance Of Common Shares For Vendor Advances | 156.0K | ||||
| Investment Income Net | $37.0K | $34.0K | $4.0K | ||
| Fair Value Of Restricted Stock Units | |||||
| Vendor Advances Current | $1.5M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.